Zobrazeno 1 - 10
of 410
pro vyhledávání: '"Philippe Merle"'
Autor:
Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Publikováno v:
Liver Cancer (2024)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpo
Externí odkaz:
https://doaj.org/article/d51ee563349d44e9ad5aa1c2a8eccf42
Autor:
Manon Falette-Puisieux, Jean-Charles Nault, Mohamed Bouattour, Marie Lequoy, Giuliana Amaddeo, Thomas Decaens, Frederic Di Fiore, Sylvain Manfredi, Philippe Merle, Aurore Baron, Christophe Locher, Anna Pellat, Romain Coriat
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives: The aim of this retro
Externí odkaz:
https://doaj.org/article/25744b0ddba64efaa454483f3d5454cd
Autor:
Yasmina Chouik, Domitille Erard, Hassan Demian, Thomas Schulz, Tessa Mazard, Kerstin Hartig-Lavie, Teresa Antonini, Jean-Yves Mabrut, Kayvan Mohkam, Agnès Rode, Philippe Merle
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundAtezolizumab plus Bevacizumab combination therapy has recently emerged as the new standard of care for unresectable HCC. Significant tumor burden reduction can be observed under that treatment, raising the question of liver transplantation
Externí odkaz:
https://doaj.org/article/fddfb6f9a47f4f0cb6caa99ef1b97137
Autor:
Cyrille Féray, Loic Campion, Philippe Mathurin, Isabelle Archambreaud, Xavier Mirabel, Jean Pierre Bronowicki, Emmanuel Rio, Christophe Perret, Laurent Mineur, Frédéric Oberti, Yann Touchefeu, Jérôme Gournay, Hélène Regnault, Julien Edeline, Agnès Rode, Patrick Hillion, Jean Frédéric Blanc, Eric Nguyen Khac, Daniel Azoulay, Alain Luciani, Athena Galetto Preglisasco, Elodie Faurel-Paul, Hélène Auble, Françoise Mornex, Philippe Merle
Publikováno v:
JHEP Reports, Vol 5, Iss 4, Pp 100689- (2023)
Background & Aims: Transcatheter arterial chemoembolisation (TACE) is recommended for patients with hepatocellular carcinoma devoid of macrovascular invasion or extrahepatic spread but not eligible for curative therapies. We compared the efficacy and
Externí odkaz:
https://doaj.org/article/fd1a246d2e394a90995bfbb4024651df
Autor:
Philippe Telouk, Marie-Laure Plissonnier, Philippe Merle, Fabien Zoulim, Nadim Fares, Paule Guilloreau, Romain Parent, Justine Bacchetta, Marc Danan, Sergio Carandina, Francis Albarède, PhD
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 3, Pp 480-486 (2022)
Background and Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, and finding a single reliable biomarker to follow liver degradation is a challenging task. To document the relationship between liver fa
Externí odkaz:
https://doaj.org/article/21e306db84c7405b920e1c21407462b6
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886
Autor:
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In
Externí odkaz:
https://doaj.org/article/a9aecdc91b464f2abd10eaa8419833fa
Autor:
Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky
Publikováno v:
Liver Cancer (2022)
Introduction: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choi
Externí odkaz:
https://doaj.org/article/be5711b659ef4aac9c021fbcc1a46bb6
Autor:
Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frédéric Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng
Publikováno v:
Liver Cancer (2022)
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficac
Externí odkaz:
https://doaj.org/article/5702df6d3dcb4d41bb1056d2e8bdf177
Autor:
Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo
Publikováno v:
Liver Cancer (2022)
Introduction The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab vs sorafenib as a first-line
Externí odkaz:
https://doaj.org/article/bffb1e2d18d848fc9f8efeb89eb97bb0